"use strict";(self.webpackChunkgenomics_docusaurus_new=self.webpackChunkgenomics_docusaurus_new||[]).push([[231],{8453:(e,n,o)=>{o.d(n,{R:()=>r,x:()=>c});var i=o(6540);const t={},s=i.createContext(t);function r(e){const n=i.useContext(s);return i.useMemo((function(){return"function"==typeof e?e(n):{...n,...e}}),[n,e])}function c(e){let n;return n=e.disableParentContext?"function"==typeof e.components?e.components(t):e.components||t:r(e.components),i.createElement(s.Provider,{value:n},e.children)}},8998:(e,n,o)=>{o.r(n),o.d(n,{assets:()=>l,contentTitle:()=>a,default:()=>p,frontMatter:()=>c,metadata:()=>i,toc:()=>d});const i=JSON.parse('{"id":"oncology-europe/incidence-cost-scenarios","title":"Incidence & Cost Scenarios","description":"High-level Genomic Sequencing Expenditure","source":"@site/docs/oncology-europe/incidence-cost-scenarios.md","sourceDirName":"oncology-europe","slug":"/oncology-europe/incidence-cost-scenarios","permalink":"/datasolutions/oncology-europe/incidence-cost-scenarios","draft":false,"unlisted":false,"tags":[],"version":"current","sidebarPosition":2,"frontMatter":{"title":"Incidence & Cost Scenarios","sidebar_position":2,"hide_title":true},"sidebar":"docsSidebar","previous":{"title":"Cancer Incidence & Projection","permalink":"/datasolutions/oncology-europe/"},"next":{"title":"German Hospital Landscape","permalink":"/datasolutions/oncology-europe/germany-hospitals"}}');var t=o(4848),s=o(8453),r=o(6025);const c={title:"Incidence & Cost Scenarios",sidebar_position:2,hide_title:!0},a=void 0,l={},d=[{value:"High-level Genomic Sequencing Expenditure",id:"high-level-genomic-sequencing-expenditure",level:2}];function u(e){const n={h2:"h2",hr:"hr",p:"p",...(0,s.R)(),...e.components};return(0,t.jsxs)(t.Fragment,{children:[(0,t.jsx)(n.h2,{id:"high-level-genomic-sequencing-expenditure",children:"High-level Genomic Sequencing Expenditure"}),"\n",(0,t.jsx)(n.hr,{}),"\n",(0,t.jsx)("div",{style:{textAlign:"justify"},children:(0,t.jsxs)(n.p,{children:["In order to have a ",(0,t.jsx)("b",{children:"high-level and initial estimation of genomic sequencing expenditure"}),", based on current (2022) and future (2050) cancer incidence, I have decided to explore a very basic scenario. Europe and North America are aggregated here as regions where ",(0,t.jsx)("b",{children:"some adoption of sequencing is already underway"}),"."]})}),"\n",(0,t.jsx)("div",{style:{textAlign:"justify"},children:(0,t.jsxs)(n.p,{children:["This approach assumes one sample per case, and explores a range of ",(0,t.jsx)("b",{children:"uptake levels"}),", defined here as the proportion of newly diagnosed cancer cases that would undergo genomic sequencing. Different cost scenarios are tested, ranging from \u20ac200 to \u20ac1000 per sample. The analysis reflects the use of ",(0,t.jsx)("b",{children:"targeted panel sequencing"}),", which is currently the most common approach in oncology for identifying actionable mutations."]})}),"\n",(0,t.jsx)("br",{}),"\n",(0,t.jsx)("br",{}),"\n",(0,t.jsx)("img",{src:(0,r.Ay)("/files/europa_america_oncology_initial.png"),alt:"Projected sequencing costs heatmap"})]})}function p(e={}){const{wrapper:n}={...(0,s.R)(),...e.components};return n?(0,t.jsx)(n,{...e,children:(0,t.jsx)(u,{...e})}):u(e)}}}]);